On 19 September 2025, GenFleet Therapeutics (Shanghai) Inc. (2595.HK, GenFleet) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 1,820 million. CBI is honored to participate in the due diligence work for this IPO Project.

GenFleet is principally engaged in the development of innovative drugs. The Company provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, suppliers and customers. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting reputation intelligence, related company search and reference check. The due diligence project globally covered 9 countries and regions, including China, Hong Kong, Canada, Australia and Spain, etc.